Literature DB >> 15632991

[Reduction of periodontoid masses following posterior arthrodesis: review of two new cases not linked to rheumatoid arthritis].

M Joly-Torta1, S Martín-Ferrer, J Rimbau-Muñoz, C Domínguez.   

Abstract

Inflamatory periodontoid pannus is quite common in patients with rheumatoid arthritis. However, the occurrence of a pannus-like periodontoid mass that is unassociated with rheumatic inflammation is less frequent. Transoral surgery associated with a posterior stabilization has long been considered one of the most efficient methods to resolve the problem of instability in patients presenting neurological deficits secondary to the pannus. We present two cases of non rheumatic etiology, in which an occipito-cervical arthrodesis was used to resolve the proliferative lesion around the odontoid apophysis. Two women (67 and 60 years old respectively) presented symptoms of pain and neurological deterioration with an antecedent of possible past odontoid fracture in one case, and a previous large anterior cervical arthrodesis to correct spondylarthrosis in the other case. Both patient's neurological condition improved after placement of an arthrodesis through a posterior approach.

Entities:  

Mesh:

Year:  2004        PMID: 15632991     DOI: 10.1016/s1130-1473(04)70442-x

Source DB:  PubMed          Journal:  Neurocirugia (Astur)        ISSN: 1130-1473            Impact factor:   0.553


  2 in total

1.  Pannus resolution after occipitocervical fusion in a non-rheumatoid atlanto-axial instability.

Authors:  Alfonso Lagares; Iñaki Arrese; Beatriz Pascual; Pedro A Gòmez; Ana Ramos; Ramiro D Lobato
Journal:  Eur Spine J       Date:  2005-12-29       Impact factor: 3.134

2.  Disappearance of degenerative, non-inflammatory, retro-odontoid pseudotumor following posterior C1-C2 fixation: case series and review of the literature.

Authors:  Giuseppe M V Barbagallo; Francesco Certo; Massimiliano Visocchi; Stefano Palmucci; Giovanni Sciacca; Vincenzo Albanese
Journal:  Eur Spine J       Date:  2013-09-19       Impact factor: 3.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.